Pulmonx (STU:4NI) Capital Expenditure : €-1.50 Mil (TTM As of Jun. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Pulmonx Capital Expenditure?

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Pulmonx's cash flow for capital expenditures for the three months ended in Jun. 2024 was €-0.44 Mil. Its cash flow for capital expenditures for the trailing twelve months (TTM) ended in Jun. 2024 was €-1.50 Mil.

Pulmonx Capital Expenditure Historical Data

The historical data trend for Pulmonx's Capital Expenditure can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pulmonx Capital Expenditure Chart

Pulmonx Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Capital Expenditure

Get a 7-Day Free Trial

-0.65

-0.75

-3.25

-1.24

-0.74

Pulmonx Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
Capital Expenditure	Get a 7-Day Free Trial															-0.05	-0.46	-0.18	-0.42	-0.44

Pulmonx Capital Expenditure Calculation

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Capital Expenditure for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.50 Mil.

Pulmonx Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Pulmonx Corp (STU:4NI) » Definitions » Capital Expenditure

Comparable Companies

Traded in Other Exchanges

LUNG:USA

Address

700 Chesapeake Drive, Redwood, CA, USA, 94063

Website

https://www.pulmonx.com

Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). the company's solutions comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the U.S. and international markets.

Pulmonx Headlines

No Headlines